Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Brand-name drug

Hysingla price, strengths & recalls

Brand of hydrocodone (generic)

Pharmacies pay $399.18 for 30 tablets of Hysingla 20 mg extended-release tablet this week, and from $399.18 to $1,459.65 across its 5 priced strengths and forms. The generic, hydrocodone, costs pharmacies from $238.16. It has 16 recalls on record, none ongoing. Its official label last changed on June 18, 2026.

Brand
Pharmacies pay$399.18for 30 tablets of 20 mg extended-release tabletNo change in 4 weeks
Fair cash price
$469.56
Strengths
5
Makers
1
Updated
Nov 11

Hysingla price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
20 mg extended-release tablet Brand$13.31$399.18 / 30 tabletsNo change+8.8%
30 mg extended-release tablet Brand$19.40$581.86 / 30 tablets+0.2%+8.3%
40 mg extended-release tablet Brand$26.12$783.73 / 30 tablets-0.1%+8.6%
60 mg extended-release tablet Brand$36.13$1,083.88 / 30 tablets-0.1%+8.0%
80 mg extended-release tablet Brand$48.66$1,459.65 / 30 tabletsNo change+8.2%
100 mg extended-release tablet BrandNot priced this week

The lowest cost per tablet is 20 mg extended-release tablet at $13.31. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.

Hysingla vs generic hydrocodone

GenericHydrocodone prices

Supply status: shortages & recalls

No shortage reportedChecked Nov 16, 2026
1 ongoing recall16 recalls on record

Recalls

Class IOngoingNov 28, 2012HYDROCODONE BITARTRATE and ACETAMINOPHEN TABLETSSuperpotent (Multiple Ingredient) Drug: Confirmed customer complaints of oversized tablets resulting in superpotent assays of both the hydrocodone and acetaminophen...Vintage Pharmaceuticals LLC DBA Qualitest Pharmaceuticals · D-057-2013Class IITerminatedNov 25, 2020Hydrocodone Bitartrate and Acetaminophen TabletsPresence of Foreign Tablet/Capsule: One bottle of Hydrocodone Bitartrate and Acetaminophen Tablets USP 10mg/325 mg contains one Losartan Potassium Tablets, USP 100 mg.Ascent Pharmaceuticals, Inc. · D-0097-2021Class IITerminatedJun 19, 2019Hydrocodone Bitartrate and Homatropine Methylbromide Oral SolutioncGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).Torrent Pharma Inc · D-1383-2019Class IITerminatedJun 19, 2019Hydrocodone Bitartrate and Homatropine Methylbromide Oral SolutioncGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).Torrent Pharma Inc · D-1384-2019Class IIITerminatedFeb 21, 2018NORCO (Hydrocodone Bitartrate and Acetaminophen) TabletsLabeling: Not Elsewhere Classified: does not have the required "CII" controlled drug classification indication on the primary label.Allergan · D-0413-2018Class IIITerminatedSep 20, 2017Hydrocodone Bitartrate and Acetaminophen Oral Solution 7.5 mg/325 mg per 15 mLLabeling: Not Elsewhere Classified; product is incorrectly labeled as Class III controlled substance instead of Class II controlled substanceVistaPharm, Inc. · D-1139-2017

Showing the 6 most relevant of 16 - all recalls.

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

What did you pay for hysingla? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedJune 18, 2026
Version17 of 16
EffectiveMay 29, 2026
Read the label

These highlights do not include all the information needed to use HYSINGLA® ER safely and effectively. See full prescribing information for HYSINGLA ER. HYSINGLA® ER (hydrocodone bitartrate) extended-release tablets, for oral use, CII Initial U.S. Approval: 1943

This drug has a boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYSINGLA ER

Addiction, Abuse, and Misuse

Because the use of HYSINGLA ER exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1)].

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of HYSINGLA ER, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of HYSINGLA ER are essential. Instruct patients to swallow HYSINGLA ER tablets whole; crushing, chewing, or dissolving HYSINGLA ER tablets can cause rapid release and absorption of a potentially fatal dose of hydrocodone [see Warnings and Precautions (5.2)].

Accidental Ingestion

Accidental ingestion of even one dose of HYSINGLA ER, especially by children, can result in a fatal overdose of hydrocodone [see Warnings and Precautions (5.2)].

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of HYSINGLA ER and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate [see Warnings and Precautions (5.3), Drug Interactions (7)].

Neonatal Opioid Withdrawal Syndrome (NOWS)

Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery [see Warnings and Precautions (5.4)].

Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)

Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription [see Warnings and Precautions (5.5)].

Cytochrome P450 3A4 Interaction

The concomitant use of HYSINGLA ER with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. Regularly evaluate patients receiving HYSINGLA ER and any CYP3A4 inhibitor or inducer [see Warnings and Precautions (5.6), Drug Interactions (7), and Clinical Pharmacology (12.3)].

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYSINGLA ER

See full prescribing information for complete boxed warning.

HYSINGLA ER exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing, and reassess regularly for these behaviors and conditions. (5.1)

Serious, life-threatening, or fatal respiratory depression may occur, especially upon initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of HYSINGLA ER are essential. Instruct patients to swallow HYSINGLA ER whole to avoid exposure to a potentially fatal dose of hydrocodone. (5.2)

Accidental ingestion of HYSINGLA ER, especially by children, can result in fatal overdose of hydrocodone. (5.2)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate. (5.3, 7)

Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery (5.4)

Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription. (5.5)

Concomitant use with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of hydrocodone. (5.6, 7, 12.3)

Recent major changes (as listed on the label)

Boxed Warning | 12/2025 |

Indications and Usage (1) | 12/2025 |

Dosage and Administration (2.2, 2.3, 2.7) | 12/2025 |

Warnings and Precautions (5.1, 5.2, 5.3, 5.14, 5.16) | 12/2025 |

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Generic makers
2 approved generic applications on the market
Last patent listed
December 21, 2031

Hysingla questions

How much does hysingla cost without insurance?

Pharmacies pay about $399.18 for 30 tablets of hysingla 20 mg extended-release tablet ($13.31 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $469.56. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is there a generic for Hysingla?

Yes: hydrocodone. Pharmacies pay from $238.16 for it. Compare hydrocodone prices.

Is hysingla in shortage?

No shortage is reported for hysingla right now. We check the national shortage list every day.

Has hysingla been recalled?

16 recalls on record, none ongoing. Recalls name specific lots - check yours.

When did the hysingla label last change?

The official label was last updated on June 18, 2026 (version 17). See what changed.

Talk about hysingla

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.